GLOBAL NPHP5 RETINAL DEGENERATION TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Global NPHP5 Retinal Degeneration Treatment Market, By Treatment Type (Gene Therapy, Cell Therapy, Drug Therapy, Others), By Indication (Retinitis Pigmentosa, Leber Congenital Amaurosis, Usher Syndrome, Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Published In : Jan 2024
Code : CMI6574
Pages :170
Formats :
Excel and PDF
Industry : Pharmaceutical

Global NPHP5 Retinal Degeneration Treatment Market Size and Trends

The global NPHP5 retinal degeneration treatment market size is expected to reach US$ 131.3 Mn by 2031 from US$ 15.7 Mn in 2024, exhibiting a compound annual growth rate (CAGR) of 35.4% during the forecast period.

Figure 2. Global NPHP5 Retinal Degeneration Treatment Market Share (%), By Treatment Type, 2024

Global NPHP5 Retinal Degeneration Treatment Market - Trends

Increasing Partnerships Among Key Market Players: Increasing adoption of inorganic growth strategies such as partnerships among key market players. For instance, on April 26, 2023, RetinAI Medical, a medical technology company, announced a partnership with Boehringer Ingelheim, a global pharmaceutical company, to improve retinal disease treatment. Under the terms of the partnership, RetinAI will test its AI tools by analyzing Boehringer Ingelheim’s imaging datasets from clinical studies and real-world evidence. The aim is to identify novel biomarkers and predictors of disease progression that could accelerate the development of urgently needed treatments.